rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ANRO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Alto Neuroscience COO sells $2.07 million in ANRO shares
      1h agoInvesting.comANRO
      Alto Neuroscience (ANRO) Reports Wider Quarterly Loss, Is The Premium Valuation Still Justified?
      2h agoYahoo FinanceANRO
      Is UnitedHealth Group (UNH) Stock Outpacing Its Medical Peers This Year?

      Here is how UnitedHealth Group (UNH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.

      Nov 17Yahoo FinanceANROUNH
      Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know
      Nov 16Yahoo FinanceANRO
      Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know
      Nov 16Yahoo FinanceANRO
      Alto Neuroscience faces pivotal 2027 as Jefferies flags three clinical catalysts
      Nov 11Yahoo FinanceANRO
      Alto Neuroscience earnings up next as investors eye 2027 catalysts By Investing.com
      Nov 10Investing.comANRO
      Alto Neuroscience (ANRO) Stock Looks Fully Priced On Book Value

      Alto Neuroscience has seen its share price move sharply over the past year, which puts a spotlight on whether that market value lines up with the strength of its balance sheet. With the stock now well above levels seen earlier in the year, investors are asking how much of that shift is supported by the company’s book value. The share price has returned 118.2% over the past year, which raises the question of how firmly that move is anchored in Alto Neuroscience’s underlying net assets. The...

      Nov 10Yahoo FinanceANRO
      Alto Neuroscience Announces Participation in Upcoming Investor Conferences

      MOUNTAIN VIEW, Calif., November 03, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:

      Nov 3Yahoo FinanceANRO
      Alto Neuroscience Inc (ANRO-N) Statistics

      Find out all the key statistics for Alto Neuroscience Inc (ANRO-N), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.

      Nov 3The Globe and MailANRO
      Alto Neuroscience Inc (ANRO-N) Dividends

      Dividend history for Alto Neuroscience Inc (ANRO-N) yield, ex-date and other distribution information to help income investors find and manage investments.

      Nov 3The Globe and MailANRO
      H.C. Wainwright raises Alto Neuroscience stock price target to $60
      Oct 20Investing.comANRO
      HC Wainwright Adjusts Alto Neuroscience Price Target to $60 From $55, Maintains Buy Rating
      Oct 19Yahoo FinanceANRO
      Alto Neuroscience Inc (ANRO-N) Insider Trade Summaries

      The latest insider stock transactions for Alto Neuroscience Inc (ANRO).

      Oct 17The Globe and MailANRO
      Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold (NYSE:ANRO)
      Oct 15Seeking AlphaANRO
      Alto Neuroscience president and CFO Smith sells $3.57m in shares
      Oct 2Investing.comANRO
      Alto Neuroscience at TD Cowen summit: pramipexole combo takes center stage
      Sep 23Investing.comANRO
      Alto Neuroscience, Inc. (ANRO) Receives a Rating Update from a Top Analyst

      Detailed price information for Alto Neuroscience Inc (ANRO-N) from The Globe and Mail including charting and trades.

      Sep 22The Globe and MailANRO
      Alto Neuroscience at H.C. Wainwright: pipeline breadth gains focus
      Sep 14Investing.comANRO
      Alto Neuroscience Announces Participation in Upcoming Investor Conferences

      MOUNTAIN VIEW, Calif., September 09, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:

      Sep 9Yahoo FinanceANRO
      Alto Neuroscience promotes Nick Smith to president and CFO
      Aug 27Investing.comANRO
      Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

      MOUNTAIN VIEW, Calif., August 27, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026.

      Aug 27Yahoo FinanceANRO
      Alto Neuroscience stock hits all-time high at 35.42 USD
      Aug 24Investing.comANRO

      This is the newest page. Registered accounts read further back.